**Gastrointestinal Stromal Tumor (GIST)**

**Adult trials (Ages 18 and older)**
- **Kit and PDGFRA (D842V) Mutations**
- **2nd or 3rd Line**
  - **PDGFRA D842V Only**
  - **2nd Line Only**
  - **3rd or 4th Line**
- **IRB #19262**
  - A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib (INTRIGUE)
- **IRB #20580**
  - Expanded Access Program for Ripretinib in Patients with Locally Advanced Unresectable or Metastatic GIST Who Have Received Treatment with Prior Therapies
- **IRB #22722**
  - Phase 1, Multi-center, Open-label Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients with Advanced Malignancies
- **IRB #17155**
  - A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced GIST
- **IRB #21229**
  - Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Subjects with Advanced Gastrointestinal Stromal Tumor
- **SDH-Mutant/deficient GIST**
  - **IRB #21884**
    - An Open-Label, Phase 2 Efficacy Study of Temozolomide in Advanced SDH Mutant/Deficient GIST

**CROSS-DISEASE TRIALS:**
- **IRB# 19992**
  - EAY131 (MATCH)
- **IRB# 18084**
  - S1609 (DART)

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold

[http://www.ohsu.edu/research/rda/so/knight.php](http://www.ohsu.edu/research/rda/so/knight.php)